A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

The average weight loss among those taking the new drug was 15.7% after 68 weeks, compared to 3.1% for those taking a placebo. Shares sank to their lowest point in over a year after the release of ...

Shares of Novo Nordisk’s (NVO) are down over 9% at the time of writing after the company announced the results from its latest weight-loss drug ...

Health experts are concerned Ozempic and other GLP-1 agonist drugs may be inappropriately prescribed to people experiencing ...

Fortunes are being blown on injectable hopes of a slimmer future but a simpler and cheaper alternative could actually be in ...

Recent figures suggest that more than half a million people are taking either Mounjaro or Wegovy (the version ... advice often given to women over 50 using weight-loss jabs. We need to move ...

Novo Nordisk said CagriSema appeared to have a safe and well-tolerated profile in the latest trial. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate ...